Journal
CANCER CELL
Volume 40, Issue 6, Pages 597-599Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.017
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01-CA184185, R01-CA233512, R01-CA262121, P01-CA250984, 4, P30-CA076292]
- Florida Department of Health [20B04]
Ask authors/readers for more resources
This study demonstrates how tumors can manipulate erythroid progenitors to promote immunosuppression. These reprogrammed cells, similar to myeloid-derived suppressor cells, are associated with poor response to immune-checkpoint inhibitors and tumor-related anemia.
In this issue of Cancer Cell, Long et al. demonstrate that tumors can reprogram erythroid progenitors into myeloid-erythroid cells that promote immunosuppression. Erythroid-differentiated myeloid cells (EDMCs) expand in cancer-bearing individuals, resemble the functionality of myeloid-derived suppressor cells (MDSCs), and correlate with poor response to immune-checkpoint inhibitors (ICIs) and tumor-related anemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available